3
On Wednesday, Bayer AG (OTC:BAYRY) reported fourth-quarter 2024 adjusted EPS of $0.28, missing the consensus of $1.00.
The company reported core earnings per share of 1.05 euros, down from 1.85 euros a year ago.
The crop science and drug company reported sales of $12.52 billion (11.73 billion euros), beating the consensus of $11.30 billion.
For the fourth quarter, Bayer reported a 22% fall in adjusted EBITDA to 2.35 billion euros.
CEO Bill Anderson called 2025 a “pivotal year” for the company. “It is the second year in Bayer’s turnaround and will be the most difficult in terms of financial performance, with net …
